Primary Sclerosing Cholangitis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Primary Sclerosing Cholangitis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, Albireo, Ipsen, Chrome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc.

[Nevada, United States] - DelveInsight's "Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Primary Sclerosing Cholangitis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Primary Sclerosing Cholangitis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Primary Sclerosing Cholangitis Market Report:
The Primary Sclerosing Cholangitis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In October, 2024: Albireo announced that their study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC).
In October, 2024: Ipsen announced that a study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression.
In August, 2024: Mirum Pharmaceuticals, Inc. announced that the purpose of their study is to determine more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
In May, 2024: Escient Pharmaceuticals, Inc announced that a phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)
As per the assessment of DelveInsight, the total diagnosed prevalent cases of PSC in the 7MM were around 53,081 in 2022, out of which the US accounted for about 30,429 cases. These cases are anticipated to increase during the forecast period (2023-2032).
The total diagnosed prevalent cases of PSC in the US were observed to be approximately57%in2022of the total cases in the 7MM, these cases are expected to increase during the study period (2019-2032).
In 2022, there were approximately 20,692 males and 9,737 females among prevalent cases of PSC which is subject to increase during the forecast period.
Key Primary Sclerosing Cholangitis Companies are as follows: Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, Albireo, Ipsen, CuromeBiosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc.
Key Primary Sclerosing Cholangitis Therapies are as follow: Ritivixibat, HK-660S, Elafibranor, Cenicriviroc, PLN-74809, Volixibat, NGM282, Cilofexor, Obeticholic, HTD 1801, PLN-74809 (bexotegrast)
Launching multiple stage Primary Sclerosing Cholangitis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Primary Sclerosing Cholangitis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Primary Sclerosing Cholangitis Overview:
According to the American Liver Foundation, primary sclerosing cholangitis (PSC) is a chronic or long-term disease that slowly damages the bile ducts. In PSC patients, the bile ducts are blocked due to inflammation and scarring or fibrosis, leading to the accumulation of bile in the liver, which gradually damages liver cells and causes cirrhosis or fibrosis of the liver. As cirrhosis progresses and the amount of scar tissue in the liver increases, the liver slowly loses its ability to function. The scar tissue may block the drainage of the bile ducts leading to bile infection.

Primary Sclerosing Cholangitis Epidemiology Segmentation:
The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Primary Sclerosing Cholangitis Diagnosed Prevalent Cases
Primary Sclerosing Cholangitis Gender-specific Diagnosed Prevalent Cases
Primary Sclerosing Cholangitis Symptom-specific Diagnosed Prevalent Cases
Primary Sclerosing Cholangitis Comorbidity-specific Diagnosed Cases

For more information about Primary Sclerosing Cholangitis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Primary Sclerosing Cholangitis Market Insights
Primary sclerosing cholangitis (PSC) is a rare, chronic, progressive liver disease characterized by inflammation and scarring of the bile ducts, which can eventually lead to liver cirrhosis and liver failure. Despite advancements in medical research, PSC remains a challenging condition with limited treatment options. The global PSC market is driven by the growing need for effective therapies, but its development is hindered by significant market barriers. This article explores the latest insights into the PSC market, drug uptake, epidemiology, market drivers, and barriers.

Primary Sclerosing Cholangitis Drugs Uptake
UDCA is the most commonly prescribed drug for PSC, though it is not an FDA-approved treatment specifically for the disease. It helps to improve bile flow and reduce liver enzyme levels.
Obeticholic acid, a farnesoid X receptor (FXR) agonist, has gained attention for its potential in treating PSC. It is currently approved for primary biliary cholangitis (PBC) and is being investigated in clinical trials for PSC.
NorUDCA is a derivative of UDCA and has shown potential in preclinical and early clinical studies for PSC. It has a different mechanism of action than UDCA, and early trials have demonstrated that NorUDCA can reduce liver enzyme levels and potentially slow disease progression.
Drugs such as seladelpar and simtuzumab have been investigated for their ability to reduce liver fibrosis in PSC patients.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Primary Sclerosing Cholangitis Therapies and Key Companies:
Ritivixibat: Albireo
HK-660S: CuromeBiosciences
Elafibranor: Ipsen
Cenicriviroc: Tobira Therapeutics, Inc.
PLN-74809: Pliant Therapeutics, Inc.
Volixibat: Mirum Pharmaceuticals, Inc.
NGM282: NGM Biopharmaceuticals, Inc
Cilofexor: Gilead Sciences
Obeticholic: Intercept Pharmaceuticals
HTD 1801: HighTide Biopharma
PLN-74809 (bexotegrast): Pliant Therapeutics, Inc.

Primary Sclerosing Cholangitis Epidemiology:
Primary Sclerosing Cholangitis is a rare condition, with an estimated incidence of 0.77 to 1.31 per 100,000 people annually and a prevalence rate of 8 to 13 per 100,000 people globally. The disease is more common in men than women, with a male-to-female ratio of approximately 2:1. PSC primarily affects individuals between the ages of 30 and 50, although it can occur at any age.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Primary Sclerosing Cholangitis Market Drivers:
Growing Research and Development
Rising Prevalence of Autoimmune Diseases
Favorable Regulatory Pathways for Orphan Drugs

Primary Sclerosing Cholangitis Market Barriers:
Lack of Disease-Modifying Therapies
High Costs of Research and Development
Slow Clinical Trial Progress
Complex Disease Mechanisms

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Primary Sclerosing Cholangitis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Primary Sclerosing Cholangitis Companies: Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, Albireo, Ipsen, CuromeBiosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc.
Key Primary Sclerosing Cholangitis Therapies: Ritivixibat, HK-660S, Elafibranor, Cenicriviroc, PLN-74809, Volixibat, NGM282, Cilofexor, Obeticholic, HTD 1801, PLN-74809 (bexotegrast)
Primary Sclerosing Cholangitis Therapeutic Assessment: Current marketed and emerging therapies
Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market drivers and Primary Sclerosing Cholangitis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Primary Sclerosing Cholangitis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Primary Sclerosing Cholangitis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. PSC Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Key Events
6. Executive Summary of PSC
7. Disease Background and Overview of Primary Sclerosing Cholangitis (PSC)
8. Epidemiology and Patient Population of PSC
9. Patient Journey
10. Emerging Drugs
11. PSC: Market Analysis
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Reimbursement and Market Access
16. Appendix
17. Bibliography
18. Report Methodology
19. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.